## Mark Mapstone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7314901/publications.pdf

Version: 2024-02-01

430754 330025 1,996 39 18 37 citations g-index h-index papers 39 39 39 4176 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Plasma phospholipids identify antecedent memory impairment in older adults. Nature Medicine, 2014, 20, 415-418.	15.2	885
2	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	4.9	179
3	Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease. Frontiers in Neurology, 2015, 6, 237.	1.1	97
4	Precision pharmacology for Alzheimer's disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
5	What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. Neurobiology of Aging, 2017, 51, 148-155.	1.5	74
6	Omics sciences for systems biology in Alzheimer's disease: State-of-the-art of the evidence. Ageing Research Reviews, 2021, 69, 101346.	5.0	74
7	Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget, 2017, 8, 68899-68915.	0.8	55
8	Distinct mechanisms of impairment in cognitive ageing and Alzheimer's disease. Brain, 2008, 131, 1618-1629.	3.7	51
9	Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naà ve HIV-infected individuals. Journal of NeuroVirology, 2017, 23, 704-712.	1.0	44
10	The cingulate cortex of older adults with excellent memory capacity. Cortex, 2017, 86, 83-92.	1.1	40
11	Personality and Performance in Specific Neurocognitive Domains Among Older Persons. American Journal of Geriatric Psychiatry, 2017, 25, 900-908.	0.6	34
12	Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 54, 69-78.	1.2	31
13	Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PLoS ONE, 2018, 13, e0195318.	1.1	30
14	Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease. Developmental Neurobiology, 2019, 79, 622-638.	1.5	29
15	Longitudinal Functional Brain Mapping in Supernormals. Cerebral Cortex, 2019, 29, 242-252.	1.6	24
16	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Journal of Alzheimer's Disease, 2021, 79, 671-681.	1.2	23
17	Frequency of Mentally Stimulating Activities Modifies the Relationship Between Cardiovascular Reactivity and Executive Function in Old Age. American Journal of Geriatric Psychiatry, 2014, 22, 1210-1221.	0.6	22
18	A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among communityâ€dwelling Mexican Americans and nonâ€Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimer's and Dementia, 2022, 18, 77-87.	0.4	21

#	Article	IF	Citations
19	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 797.	4.5	17
20	Toward Reproducible Results from Targeted Metabolomic Studies: Perspectives for Data Pre-processing and a Basis for Analytic Pipeline Development. Current Topics in Medicinal Chemistry, 2018, 18, 883-895.	1.0	16
21	A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease, 2020, 78, 1381-1392.	1.2	16
22	Potential Metabolomic Linkage in Blood between Parkinson's Disease and Traumatic Brain Injury. Metabolites, 2018, 8, 50.	1.3	14
23	Mental Fatigability and Heart Rate Variability in Mild Cognitive Impairment. American Journal of Geriatric Psychiatry, 2016, 24, 374-378.	0.6	13
24	Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium–Down Syndrome (ABC–DS) study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12039.	1.2	13
25	Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer's pathology. Brain Imaging and Behavior, 2019, 13, 53-64.	1.1	12
26	Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12028.	1.2	12
27	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12062.	1.2	12
28	Impact of the COVID-19 pandemic on daily life, mood, and behavior of adults with Down syndrome. Disability and Health Journal, 2022, 15, 101278.	1.6	12
29	A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer's disease. GeroScience, 2022, 44, 1525-1550.	2.1	12
30	Plasma Sphingomyelins in Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 1161-1171.	1.2	9
31	Memory timeline: Brain ERP C250 (not P300) is an early biomarker of short-term storage. Brain Research, 2015, 1604, 74-83.	1.1	8
32	TGF $\hat{l}^2$ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGF $\hat{l}^2$ Induced EMT in PDAC. Cancers, 2021, 13, 6204.	1.7	8
33	Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome. Neuron, 2022, 110, 2063-2079.	3.8	8
34	Biomarker validation: Methods and matrix matter. Alzheimer's and Dementia, 2017, 13, 608-609.	0.4	7
35	Cognitively supernormal older adults maintain a unique structural connectome that is resistant to Alzheimer's pathology. Neurolmage: Clinical, 2020, 28, 102413.	1.4	6
36	Apolipoprotein E genotype impact on memory and attention in older persons: the moderating role of personality phenotype. International Journal of Geriatric Psychiatry, 2018, 33, 332-339.	1.3	5

#	Article	IF	CITATIONS
37	Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 604-614.	1.2	3
38	Proteomic and metabolomic biomarkers of Alzheimer's disease: Opportunities to advance precision medicine and clinical trials., 2022,, 129-147.		1
39	Blood Biomarkers of Cognitive Health and Neurodegenerative Disease. , 2020, , 568-586.		O